Stock Market Stories and Insights

<div class='circular--portrait-small' style='font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;padding-top: 10px;;'>EP</div>
  3 days ago at Macroaxis 
By Gabriel Shpitalnik
It appears Eagle Pharmaceuticals may not have a good chance to recover from the current slide as its shares fell again. This firm's current daily volatility is 2.54 percent, with a beta of -0.03 and an alpha of -0.17 over DOW. While many traders are getting carried away by overanalyzing market volatility, it is reasonable to break down Eagle Pharmaceuticals based on how it reacts to the current economic swings. We will cover the possibilities of making Eagle Pharmaceuticals into a steady grower in September.
<div class='circular--portrait-small' style='font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>TM</div>
  3 days ago at Macroaxis 
By Vlad Skutelnik
While some of us are excited about communication services space, it makes sense to recap Townsquare Media in greater detail to make a better perception of its potential. As we have suggested previously, Townsquare Media is beginning its decline as insiders shift to be more bearish due to the increased sector volatility. The returns on investing in Townsquare Media and the market returns of the last few months appear highly unrelated. Unfluctuating basic indicators of the firm may also hint at signs of long period losses for Townsquare insiders. Townsquare Media is scheduled to announce its earnings today.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:0.9em;padding-top: 12px;;'>CEV</div>
  3 days ago at Macroaxis 
By Ellen Johnson
With so much uncertainty about the technology space, it is fair to go over CEVA Inc against current market trends. As expected, CEVA is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The returns on investing in CEVA and the market returns of the last few months appear uncorrelated. The appearance of strong basic indicators of the company suggests a short-term price swing for investors of CEVA. CEVA Inc is scheduled to announce its earnings today. The next earnings report is expected on the 5th of November 2020. The stock is in a buyout trend.
<div class='circular--portrait-small' style='font-weight: 700;background:#3b5998;color: #F0F8FF;font-size:1.1em;padding-top: 10px;;'>PP</div>
  3 days ago at Macroaxis 
By Achuva Shats
Par Pacific Inventory Turnover is relatively stable at the moment as compared to the past year. Par Pacific reported last year Inventory Turnover of 10.24. As of 08/10/2020, Accrued Expenses Turnover is likely to grow to 62.21, while Average Assets are likely to drop slightly above 2.1 B. Par Pacific Holdings is scheduled to announce its earnings today. The next earnings report is expected on the 2nd of November 2020. Although many conservative investors are getting more into energy space, we should study Par Pacific's latest fundamentals in more details. What exactly are Par Pacific shareholders getting in September? The firm barely shadows the market. We can now discuss Par Pacific as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;padding-top: 10px;;'>RP</div>
  3 days ago at Macroaxis 
By Achuva Shats
As many of us are excited about healthcare space, it is fair to go over Reata Pharmaceuticals within current market trends. As expected, Reata Pharmaceuticals is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The returns on investing in Reata Pharmaceuticals and the market returns of the last few months appear uncorrelated. Weak basic indicators of the company may also suggest signs of long term losses for Reata investors. Reata Pharmaceuticals is scheduled to announce its earnings today. The next earnings report is expected on the 10th of November 2020. The stock is undergoing an active downward rally.
<div class='circular--portrait-small' style='font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>TM</div>
  2 days ago at Macroaxis 
By Raphi Shpitalnik
Townsquare Media is scheduled to announce its earnings today. Townsquare Media Cash and Equivalents Turnover is very stable at the moment as compared to the past year. Townsquare Media reported last year Cash and Equivalents Turnover of 5.91. As of 10th of August 2020, Cash Flow Per Share is likely to grow to 2.47, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (11.5 M). While some of us are becoming more enthusiastic about communication services space, let's recap Townsquare Media in greater detail to make a better estimate of its debt utilization.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;padding-top: 10px;;'>NT</div>
  3 days ago at Macroaxis 
By Raphi Shpitalnik
Neos Therapeutics Working Capital is relatively stable at the moment as compared to the past year. Neos Therapeutics reported last year Working Capital of 3.2 Million. As of 08/10/2020, PPandE Turnover is likely to grow to 9.14, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (5.1 M). While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to sum up Neos Therapeutics. We will evaluate if Neos Therapeutics shares are reasonably priced going into September. In this post, I will also go over a few different drivers affecting Neos Therapeutics' products and services, and explain how it may impact Neos Therapeutics retail investors.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #f7f7f7;font-size:1.1em;padding-top: 10px;;'>SY</div>
  3 days ago at Macroaxis 
By Raphi Shpitalnik
Synchronoss Technolo is scheduled to announce its earnings today. The next earnings report is expected on the 2nd of November 2020. As many retail investors are getting excited about technology space, it is fair to sum up Synchronoss outlook under the latest economic conditions. We will analyze why Synchronoss investors may still consider a stake in the business given the latest economic outlook.
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.1em;padding-top: 10px;;'>MP</div>
  3 days ago at Macroaxis 
By Achuva Shats
Momenta Pharmaceuticals is scheduled to announce its earnings today. The next earnings report is expected on the 29th of October 2020. The stock is undergoing an active downward rally. As many millenniums are getting excited about healthcare space, it is only fair to go over the feasibility of shorting Momenta Pharmaceuticals. We will cover the possibilities of Momenta Pharmaceuticals recovering given the current economic outlook.
<div class='circular--portrait-small' style='font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;padding-top: 10px;;'>SE</div>
  3 days ago at Macroaxis 
By Achuva Shats
SeaWorld Entertainment Market Capitalization is relatively stable at the moment as compared to the past year. SeaWorld Entertainment reported last year Market Capitalization of 2.03 Billion. As of 08/10/2020, Tangible Asset Value is likely to grow to about 2.3 B, while Free Cash Flow is likely to drop slightly above 103.8 M. SeaWorld Entertainment is scheduled to announce its earnings today. The next earnings report is expected on the 5th of November 2020. As some conservatives are trying to avoid consumer cyclical space, we'll sum up SeaWorld Entertainment a little further and explain its current market possibilities. I will address the reasons this entity was abused by retail investors resulted from the current market uncertainty. We currently estimate SeaWorld Entertainment as fairly valued. The real value is approaching 16.67 per share.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page